GWM Advisors LLC raised its stake in shares of Johnson & Johnson (NYSE:JNJ) by 81.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 28,374 shares of the company’s stock after buying an additional 12,741 shares during the period. GWM Advisors LLC’s holdings in Johnson & Johnson were worth $3,372,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the stock. Nationwide Fund Advisors raised its stake in Johnson & Johnson by 10.6% in the third quarter. Nationwide Fund Advisors now owns 2,130,188 shares of the company’s stock valued at $251,639,000 after buying an additional 203,457 shares in the last quarter. Wright Investors Service Inc. raised its stake in Johnson & Johnson by 59.0% in the third quarter. Wright Investors Service Inc. now owns 2,830 shares of the company’s stock valued at $334,000 after buying an additional 1,050 shares in the last quarter. Cullen Frost Bankers Inc. raised its stake in Johnson & Johnson by 0.3% in the third quarter. Cullen Frost Bankers Inc. now owns 209,692 shares of the company’s stock valued at $24,771,000 after buying an additional 612 shares in the last quarter. Round Table Services LLC raised its stake in Johnson & Johnson by 2.6% in the third quarter. Round Table Services LLC now owns 4,442 shares of the company’s stock valued at $525,000 after buying an additional 111 shares in the last quarter. Finally, Asset Advisors Corp raised its stake in Johnson & Johnson by 0.5% in the third quarter. Asset Advisors Corp now owns 169,151 shares of the company’s stock valued at $19,982,000 after buying an additional 898 shares in the last quarter. Hedge funds and other institutional investors own 64.13% of the company’s stock.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Shares of Johnson & Johnson (NYSE:JNJ) traded down 0.88% on Monday, reaching $113.13. The company had a trading volume of 9,065,730 shares. The company has a market capitalization of $307.77 billion, a PE ratio of 19.86 and a beta of 0.75. The company’s 50-day moving average is $115.97 and its 200-day moving average is $118.40. Johnson & Johnson has a one year low of $94.28 and a one year high of $126.07.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 18th. The company reported $1.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.66 by $0.02. Johnson & Johnson had a net margin of 22.03% and a return on equity of 25.30%. The business had revenue of $17.80 billion for the quarter, compared to analysts’ expectations of $17.71 billion. During the same quarter in the previous year, the firm posted $1.49 EPS. The business’s revenue for the quarter was up 4.2% compared to the same quarter last year. Equities research analysts predict that Johnson & Johnson will post $6.72 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 6th. Shareholders of record on Tuesday, November 22nd will be issued a dividend of $0.80 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.29. The ex-dividend date of this dividend is Friday, November 18th. This represents a $3.20 dividend on an annualized basis and a yield of 2.80%. Johnson & Johnson’s payout ratio is presently 56.64%.

WARNING: This story was posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark law. The correct version of this story can be read at https://www.thecerbatgem.com/2016/11/28/johnson-johnson-jnj-shares-bought-by-gwm-advisors-llc.html.

A number of equities analysts have recently weighed in on JNJ shares. Vetr upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $124.21 target price on the stock in a research note on Monday, August 22nd. Zacks Investment Research upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $139.00 target price on the stock in a research note on Friday, August 5th. BTIG Research reiterated a “neutral” rating on shares of Johnson & Johnson in a research note on Wednesday, September 7th. RBC Capital Markets set a $133.00 target price on Johnson & Johnson and gave the stock a “buy” rating in a research note on Wednesday, November 9th. Finally, Credit Suisse Group AG reiterated a “neutral” rating and set a $123.00 target price on shares of Johnson & Johnson in a research note on Monday, September 19th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $121.02.

In other Johnson & Johnson news, Director Charles Prince bought 875 shares of the stock in a transaction on Friday, October 21st. The shares were acquired at an average price of $114.11 per share, with a total value of $99,846.25. Following the acquisition, the director now directly owns 26,520 shares of the company’s stock, valued at approximately $3,026,197.20. The transaction was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 0.11% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

5 Day Chart for NYSE:JNJ

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.